On 17 October 2019, orphan designation EU/3/19/2211 was granted by the European Commission to Therapharm Deutschland GmbH, Germany, for besilesomab for treatment in haematopoietic stem cell transplantation.
The sponsorship was transferred to Advanced Nuclear Medicine Ingredients, Belgium, in October 2021.
Treatment in haematopoietic stem cell transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: